Drug intelligence / Profile preview

RU78300

Development stage: Preclinical
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules

Overview

RU78300 is an experimental small molecule compound classified as a phenyl phosphate derivative. It has the chemical formula C8H9O6P and is not approved for clinical use in any country. The primary mechanism of action identified for RU78300 is inhibition of the proto-oncogene tyrosine-protein kinase Src, a non-receptor tyrosine kinase involved in various cellular signaling pathways, including those regulating cell growth and differentiation. The drug has been studied primarily at the preclinical or early research stage, with no reported clinical trials beyond phase 0[1][2][3][7].

Other names: 2-formyl-6-methoxyphenyl dihydrogen phosphate(2-methanoyl-6-methoxy-phenyl) dihydrogen phosphate

Targets

SRC (Proto-oncogene tyrosine-protein kinase Src)

Beyond the preview

Go deeper on RU78300.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RU78300.

Explore the full profile